LAVA Therapeutics NV
LVTX
View Detailed Chart
1.615USD
-0.010-0.62%
Close 11/05, 16:00（ET）Quotes delayed by 15 min
42.48MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.62%
5 Days
+0.62%
1 Month
+0.94%
6 Months
+30.24%
Year to Date
+69.82%
1 Year
-11.26%
View Detailed Chart
TradingKey Stock Score of LAVA Therapeutics NV
Currency: USD Updated: 2025-11-05Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
LAVA Therapeutics NV's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Hold
Current Rating
1.370
Target Price
-15.69%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
LAVA Therapeutics NV Highlights
StrengthsRisks
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Growing
The company is in a growing phase, with the latest annual income totaling USD 11.98M.
Fairly Valued
The company’s latest PE is -1.53, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 7.48M shares, decreasing 38.60% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.49.
LAVA Therapeutics NV News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
LAVA Therapeutics NV Info
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Ticker SymbolLVTX
CompanyLAVA Therapeutics NV
CEOMr. Stephen A. Hurly
Websitehttps://www.lavatherapeutics.com/
Related Instruments
+2.09%
-0.46%
+0.41%
-1.07%
+0.39%
+0.63%
+7.81%
+0.44%
-0.34%
+1.28%
-0.22%
-1.11%
+0.31%
+1.93%
-0.28%
-0.11%
0.00%
+2.58%
+2.62%
-3.19%Popular Symbols
